Search Results - "Tusquets, Ignasi"

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations by Tamborero, David, Rubio-Perez, Carlota, Deu-Pons, Jordi, Schroeder, Michael P, Vivancos, Ana, Rovira, Ana, Tusquets, Ignasi, Albanell, Joan, Rodon, Jordi, Tabernero, Josep, de Torres, Carmen, Dienstmann, Rodrigo, Gonzalez-Perez, Abel, Lopez-Bigas, Nuria

“…While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important…”
Get full text

Breast density, benign breast disease, and risk of breast cancer over time by Román, Marta, Louro, Javier, Posso, Margarita, Alcántara, Rodrigo, Peñalva, Lupe, Sala, Maria, del Riego, Javier, Prieto, Miguel, Vidal, Carmen, Sánchez, Mar, Bargalló, Xavier, Tusquets, Ignasi, Castells, Xavier

“…Objectives Assessing the combined effect of mammographic density and benign breast disease is of utmost importance to design personalized screening strategies…”
Get full text

Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer by Sabbaghi, MohammadA, Gil-Gómez, Gabriel, Guardia, Cristina, Servitja, Sonia, Arpí, Oriol, García-Alonso, Sara, Menendez, Silvia, Arumi-Uria, Montserrat, Serrano, Laia, Salido, Marta, Muntasell, Aura, Martínez-García, Maria, Zazo, Sandra, Chamizo, Cristina, González-Alonso, Paula, Madoz-Gúrpide, Juan, Eroles, Pilar, Arribas, Joaquin, Tusquets, Ignasi, Lluch, Ana, Pandiella, Atanasio, Rojo, Federico, Rovira, Ana, Albanell, Joan

“…Trastuzumab-emtansine (T-DM1) is a standard treatment in advanced HER2-positive breast cancer. However, resistance inevitably occurs. We aimed to identify…”
Get full text

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy by Muntasell, Aura, Cabo, Mariona, Servitja, Sonia, Tusquets, Ignasi, Martínez-García, María, Rovira, Ana, Rojo, Federico, Albanell, Joan, López-Botet, Miguel

“…Overexpression of the human epidermal growth factor receptor 2 (HER2) defines a subgroup of breast tumors with aggressive behavior. The addition of…”
Get full text

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study by Pineda-Moncusí, Marta, Garcia-Giralt, Natalia, Diez-Perez, Adolfo, Tusquets, Ignasi, Servitja, Sonia, Albanell, Joan, Prieto-Alhambra, Daniel, Nogués, Xavier

“…Background: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events,…”
Get full text

Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study by O'Cearbhaill, Roisin, Pérez-Fidalgo, Jose Alejandro, Monk, Bradley, Tusquets, Ignasi, McCormick, Colleen, Fuentes, Jose, Moore, Richard, Vulsteke, Christof, Shahin, Mark, Forget, Frédéric, Bradley, William, Hietanen, Sakari, O'Malley, David, Dørum, Anne, Slomovitz, Brian, Baumann, Klaus, Selle, Frédéric, Calvert, Paula, Artioli, Grazia, Levy, Tally, Kumar, Aalok, Malinowska, Izabela, Li, Yong, Gupta, Divya, González-Martín, Antonio

“…Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved as maintenance treatment for patients (pts) with newly diagnosed advanced or recurrent…”
Get full text

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study by Garcia-Giralt, Natalia, Rodríguez-Sanz, María, Prieto-Alhambra, Daniel, Servitja, Sonia, Torres-del Pliego, Elisa, Balcells, Susana, Albanell, Joan, Grinberg, Daniel, Diez-Perez, Adolfo, Tusquets, Ignasi, Nogués, Xavier

“…A major side effect of aromatase inhibitor (AI) therapy is AI-related arthralgia (AIA), which often leads to therapy discontinuation. We aimed to identify…”
Get full text

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance by Servitja, Sonia, Martos, Tamara, Rodriguez Sanz, Maria, Garcia-Giralt, Natalia, Prieto-Alhambra, Daniel, Garrigos, Laia, Nogues, Xavier, Tusquets, Ignasi

“…Aromatase inhibitors (AIs) are routinely used in the adjuvant treatment of women with hormone receptor-positive early breast cancer. Patients who receive AIs…”
Get full text

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma by COLOMER, Ramon, MONZO, Mariano, LLOMBART, Antonio, PLAZAOLA, Arrate, ARTELLS, Rosa, GILABERT, Monstsrrat, LLOVERAS, Belen, ALBA, Emilio, TUSQUETS, Ignasi, RIFA, Juli, BAENA, José M, BARNADAS, Agusti, CALVO, Lourdes, CARABANTES, Francisco, CRESPO, Carmen, MUNOZ, Montserrat

“…Purpose: To evaluate the efficacy of treatment with the aromatase inhibitor letrozole in breast cancer patients segregated with respect to DNA polymorphisms of…”
Get full text

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin by ROJO, Federico, GONZALEZ-NAVARRETE, Irene, SANCHEZ-PEREZ, Isabel, CAMPAS, Clara, COROMINAS, Josep Maria, TUSQUETS, Ignasi, BELLOSILLO, Beatriz, SERRANO, Sergi, PERONA, Rosario, ROVIRA, Ana, ALBANELL, Joan, BRAGADO, Rafael, DALMASES, Alba, MENENDEZ, Silvia, CORTES-SEMPERE, Maria, SUAREZ, Cristina, OLIVA, Cristina, SERVITJA, Sonia, RODRIGUEZ-FANJUL, Vanesa

“…Purpose: Mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) dephosphorylates mitogen-activated protein kinase [extracellular signal-regulated kinase…”
Get full text

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile by González-Martín, Antonio, Alba, Emilio, Ciruelos, Eva, Cortés, Javier, Llombart, Antonio, Lluch, Ana, Andrés, Raquel, Álvarez, Isabel, Aramendía, José Manuel, de la Peña, Francisco Ayala, Barnadas, Agustí, Batista, Norberto, Calvo, Lourdes, Galve, Elena, García-Palomo, Andrés, García-Sáenz, José Ángel, de la Haba, Juan, López, Rafael, López-Vivanco, Guillermo, Martínez-Jáñez, Noelia, de Dueñas, Eduardo Martínez, Plazaola, Arrate, Rodríguez-Lescure, Álvaro, Ruiz, Manuel, Sánchez-Rovira, Pedro, Santaballa, Ana, Seguí, Miguel Ángel, Tusquets, Ignasi, Zamora, Pilar, Martín, Miguel

“…Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent…”
Get more information

Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer by CIRERA, L, BALIL, A, BOLEDA, M, BATISTE-ALENTORN, E, TUSQUETS, I, CARDONA, T, ARCUSA, A, JOLIS, L, SAIGI, E, GUASCH, I, BADIA, A

“…The efficacy of adjuvant chemotherapy in gastric cancer is controversial. We conducted a phase III, randomized, multicentric clinical trial with the goal of…”
Get full text

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry by Salido, Marta, Tusquets, Ignasi, Corominas, Josep M, Suarez, Marta, Espinet, Blanca, Corzo, Cristina, Bellet, Meritxell, Fabregat, Xavier, Serrano, Sergi, Solé, Francesc

“…Abstract Introduction One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2…”
Get full text

Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study by Pineda-Moncusí, Marta, Servitja, Sonia, Tusquets, Ignasi, Diez-Perez, Adolfo, Rial, Albora, Cos, Maria Lourdes, Campodarve, Isabel, Rodriguez-Morera, Jaime, Garcia-Giralt, Natalia, Nogués, Xavier

“…Purpose The most frequent adverse effects of aromatase inhibitors (AI) are arthralgia and bone loss induction. These reduce the quality of life of patients and…”
Get full text

Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates by Pineda‐Moncusí, Marta, Garcia‐Giralt, Natalia, Diez‐Perez, Adolfo, Servitja, Sonia, Tusquets, Ignasi, Prieto‐Alhambra, Daniel, Nogués, Xavier

“…ABSTRACT Aromatase inhibitors have been associated with accelerated bone loss and an increased risk of osteoporotic fractures. Currently, bisphosphonates are…”
Get full text

Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors by Lluch, Ana, Álvarez, Isabel, Muñoz, Montserrat, Seguí, Miguel Ángel, Tusquets, Ignasi, García-Estévez, Laura

“…Abstract In spite of recent advances in the treatment of metastatic breast cancer, this disease remains essentially incurable. Anthracyclines and taxanes have…”
Get full text

Total Effective Xenoestrogen Burden in Serum Samples and Risk for Breast Cancer in a Population-Based Multicase-Control Study in Spain by Pastor-Barriuso, Roberto, Fernández, Mariana F, Castaño-Vinyals, Gemma, Whelan, Denis, Pérez-Gómez, Beatriz, Llorca, Javier, Villanueva, Cristina M, Guevara, Marcela, Molina-Molina, José-Manuel, Artacho-Cordón, Francisco, Barriuso-Lapresa, Laura, Tusquets, Ignasi, Dierssen-Sotos, Trinidad, Aragonés, Nuria, Olea, Nicolás, Kogevinas, Manolis, Pollán, Marina

“…Most studies on endocrine-disrupting chemicals and breast cancer have focused on single compounds and have produced inconclusive findings. We assessed the…”
Get full text

Bone health evaluation one year after aromatase inhibitors completion by Pineda-Moncusí, Marta, Servitja, Sonia, Casamayor, Guillem, Cos, Maria Lourdes, Rial, Abora, Rodriguez-Morera, Jaime, Tusquets, Ignasi, Diez-Perez, Adolfo, Garcia-Giralt, Natalia, Nogués, Xavier

“…Breast cancer patients treated with aromatase inhibitors (AIs) experience increased bone loss during their treatment. However, there is little information…”
Get full text

Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study by Prieto-Alhambra, Daniel, Javaid, M. Kassim, Servitja, Sonia, Arden, Nigel K, Martinez-García, Maria, Diez-Perez, Adolfo, Albanell, Joan, Tusquets, Ignasi, Nogues, Xavier

“…Aromatase inhibitor (AI)-associated arthralgia limits adherence to therapy in breast cancer. The pathophysiology may involve vitamin D status. We wished to…”
Get full text

Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial by Bianchini, Giampaolo, Smart, Chanel, Mansutti, Mauro, Lück, Hans-Joachim, Zambelli, Stefania, Olier, Clara, Anton, Antonio, Bisagni, Giancarlo, Merlini, Laura, Murillo, Serafin Morales, Calvo Martínez, Lourdes, Chacon, Jose Ignacio, Semiglazov, Vladimir, Thill, Marc, Chan, Arlene, Tusquets, Ignasi, Licata, Luca, Valagussa, Pinuccia, Viale, Giuseppe, Gianni, Luca

“…Abstract only 555 Background: We assessed TILs and PDL1 expression before, during and after neoadjuvant treatment in TNBC patients enrolled in the ETNA study,…”
Get full text